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Summary 
Inflammatory bowel disease (IBD) is associated with neutrophil infiltration into the 
mucosa and crypt abscesses. The chemokine IL-8 (murine homologs KC and MIP-2) 
and its receptor CXCR2 are required for neutrophil recruitment; thus, blocking this 
engagement is a potential therapeutic strategy. In the present study we developed a 
pre-clinical model of neutrophil migration suitable for investigating the biology of and 
testing new drugs that target neutrophil migration. Peritoneal exudate neutrophils 
from transgenic β-actin-luciferase mice were isolated 12 hours after intraperitoneal 
injection with thioglycollate and were phenotypically and functionally assessed. 
Exudate cells were injected intravenously into recipients with dextran sodium 
sulphate (DSS)-induced colitis followed by bioluminescence imaging of whole-body 
and ex vivo organs at 2, 4 and 16-22 hours post-transfer. Anti-KC antibody or an 
isotype control were administered at 20μg/mouse 1 hour before transfer followed by 
whole-body and organ imaging 4 hours post-transfer. The peritoneal exudate 
consisted of 80% neutrophils, 39% of which were CXCR2+. In vitro migration 
towards KC was inhibited by anti-KC. Ex vivo bioluminescent imaging showed that 
neutrophil trafficking into the colon of DSS recipients was inhibited by anti-KC, 4 
hours post cell transfer. In conclusion, this study describes a new approach for 
investigating neutrophil trafficking that can be used in pre-clinical studies to evaluate 
potential inhibitors of neutrophil recruitment. 
 
Keywords: Inflammatory bowel disease; neutrophils; DSS colitis; bioluminescence 
imaging 
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Introduction 
Polymorphonuclear (PMN) neutrophil transmigration across the mucosa and into 
intestinal crypts is a major characteristic of the Inflammatory bowel diseases (IBD): 
Crohn’s disease (CD) and Ulcerative colitis (UC). Excessive or unchecked neutrophil 
recruitment can lead to tissue damage mainly due to the persistent release of harmful 
inflammatory cytokines, reactive oxygen species and proteases by the infiltrated cells 
[1]. In active IBD, histological evidence of high density neutrophil accumulation in 
the intestinal lumen directly correlates with epithelial injury and clinical disease 
activity [2]. Therefore, targeting neutrophil influx is a potential therapeutic strategy 
for IBD.  
 
The CXC chemokines; human Interleukin-8 (IL-8/CXCL8) and the murine functional 
homologs keratinocyte-derived chemokine (KC/CXCL1) and macrophage 
inflammatory protein-2 (MIP-2/CXCL2) are neutrophil chemoattractants, that 
orchestrate their activation and recruitment from the blood into sites of infection, 
inflammation and injury by promoting endothelial adhesion and transmigration [3]. 
Their biological effects are mediated by binding to two high affinity receptors; 
CXCR1 and CXCR2 [4]. CXCR2 has proven to be a potent mediator of PMN 
recruitment in pre-clinical models of arthritis [5], allergy [6],  respiratory disease [7] 
and ulcerative colitis [8]. Increased mucosal expression of these chemokine receptors 
and their ligands in IBD explains the massive influx of leukocytes in active disease. 
The up-regulation of IL-8 in the colonic mucosa of IBD patients [9, 10] correlates 
well with the histological degree of inflammation  and chemokine mRNA expression 
[11] [12]. The pivotal involvement of KC and MIP-2 in PMN infiltration into 
inflammatory sites is also well documented [13] [14]. Furthermore, a marked increase 
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in KC and MIP-2 have been reported in colons of mice with acute phase dextran 
sulphate sodium (DSS) -induced colitis [15].  
 
Traditional methods used to track neutrophil recruitment such as static histological 
analysis of fixed tissues following adoptive transfer of dye-labeled cells, do not 
provide temporal or spatial information within the physiological environment of 
lymphoid tissues [16]. While, white cell scintigraphy has been used to study 
neutrophil migration in both pre-clinical and clinical  IBD studies [17, 18] there are 
well recognized disadvantages associated with radiotracers including the adverse 
effect on cell viability, radioactive decay and poor resolution [19]. In this study, a 
novel method to track neutrophil recruitment is described; involving bioluminescence 
imaging of adoptively transferred luciferase-expressing peritoneal exudate cells. We 
also investigated the blocking effect that an anti-KC antibody may have on neutrophil 
homing to the inflamed intestines of mice with DSS-induced colitis. The results from 
these studies clearly show selective trafficking of luciferase-expressing cells to 
inflamed colon 4h post cell transfer with a significant reduction in neutrophil 
trafficking in the anti-KC treated DSS mice.  
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Materials and Methods 
Mice 
Male and female wild-type (wt) FVB/N mice, 8-12 wk old, were obtained from 
Harlan (UK). The β-actin/luciferase expressing (luc+) transgenic FVB/N mice were 
purchased from Caliper Life Sciences, Alameda, CA, USA. All mice were housed 
individually and in a conventional environment (temperature 21°C, 12h light: 12h 
darkness, humidity 50%) in a dedicated animal holding facility. They were fed a 
standard non-sterile pellet diet and tap water ad libitum. Mice were allowed ≥2 wk to 
acclimatize before entering the study. All animal procedures were performed 
according to national ethical guidelines. 
 
Colitis Induction and Assessment: DSS model  
For the bioluminescence imaging studies, acute colitis was induced in the recipient 
wild-type FVB/N mice by administering 4% DSS (47 kDa, TdB Consultancy, 
Uppsala, Sweden) in drinking water. The mice were exposed to DSS for 5 days 
followed by one day on tap water. DSS was changed once during the 5 days. Disease 
progression was assessed by monitoring body weight loss, stool consistency 
(0=normal, well-formed pellets, 1=changed formed pellets, 2=loose stool, 
3=diarrhoea) and fur texture/posture (0=smooth coat/ not hunched, 1=mildly 
scruffy/mildly hunched, 2=very scruffy/very hunched) which were recorded to 
generate a daily disease activity index (DDAI). Distal colonic tissue samples were 
collected, weighed and homogenized in 50ml PBS + 2 protease inhibitor cocktail 
tablets (Roche, UK) + 10% FCS (Gibco, UK). Homogenates were centrifuged for 12 
minutes at 14,000 RPM at 4°C. Chemokine and cytokine levels were measured in the 
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supernatants using a Meso Scale Discovery (MSD) 96-well mouse pro-inflammatory 
7 plex kit and the electro-chemiluminescent multiplex system Sector 2400 imager 
(Meso Scale Discovery, Gaithersburg, MD, USA), as per manufacturers instructions.  
 
Induction of peritonitis and isolation of luc+ donor neutrophils  
Peritoneal exudate cells are primed, highly chemotactic and more functionally 
responsive in comparison to blood PMN leukocytes [20]. Thus, we chose to isolate 
these cells for both the in vitro and in vivo studies. Localized inflammation was 
induced in the peritoneal cavity of mice by intraperitoneal (i.p) injection of 4% 
thioglycollate (Difco, Detroit, MI, USA) broth that had been previously autoclaved 
and stored at 4°C. Approximately 12 hours later, a peritoneal lavage was performed 
on the mice following sacrifice by decapitation. Briefly, 5ml of harvest medium {1x 
sterile Ca2+/ Mg2+- free PBS (pH 7.2, Gibco) supplemented with 0.02% EDTA 
(Sigma-Aldrich Ireland) and 0.5% heat-inactivated FCS (Gibco)}, was injected into 
the peritoneal cavity. The peritoneal wall was then gently massaged and the fluid 
withdrawn. This was repeated twice with 80-90% recovery of the lavage fluid. The 
lavage fluid was pooled and centrifuged at 300 x g for 10 minutes at 25°C to recover 
leukocytes. The lavage solution was washed twice by re-suspending in 10ml sterile 
PBS (Gibco) and centrifuging at 300 x g for 10 minutes. Leukocytes were counted 
using a haemocytometer. Approximately 5 x 106 cells per mouse were harvested. 
 
Phenotypic Characterization of the peritoneal exudate using FACS analysis 
Peritoneal exudate cells from three wild-type FVB/N mice were isolated and pooled 
as described above and re-suspended at 1 x 106 cells/ml. To this cell suspension; 50μL 
of each mAb dye mix was added with incubation in the dark at 4oC for 30 minutes. 
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The mAbs used for flow cytometry included; anti-CD11c (IgG1) phycoerythrin 
cyanine dye 7 (PE-Cy7) HL3, anti-Ly6G (IgG2b) PE RB6-8C5, anti-CD4 (IgG2a) PE 
RM4-5, anti-CD49b (IgM) flourescein isothiocyanate (FITC) DX5 (all from BD 
Pharmingen, UK), anti-F4/80 (IgG2b) TRI-COLOR BM8 (Caltag, UK), anti-CD8 
(IgG1) PE, anti-CD3 (IgG2B) FITC, anti-CXCR2 (IgG2a) allophycocyanin (APC) 
(R&D Systems, UK), and anti-B220 (IgG2a) Alexafluor (AF) 700 RA3-6B2 (Serotec, 
UK). For analysis of activation marker expression the mAbs used were anti-CD11b 
(IgG2b) FITC MI/70 and anti-CD69 (IgG1) PE-Cy7 H1.2F3 (BD Pharmingen). 
Following staining, the cells were washed twice with blocking buffer {PBS + 1% 
bovine serum albumin (BSA, Sigma-Aldrich) + 1% rat serum (Sigma-Aldrich) + 1% 
hamster serum (Sigma-Aldrich) + 1% mouse serum (Dako Diagnostics, Ireland) + 
0.1% sodium azide (Sigma-Aldrich)} and fixed in 3% formalin for analysis. Relative 
fluorescence intensities were measured using a LSRII cytometer and BD Diva 
software (Becton Dickinson, UK). For each sample 20,000 events were recorded. The 
percentage of cells labeled with each mAb was calculated in comparison with cells 
stained with isotype control antibody. Background staining was controlled by labeled 
isotype controls (BD Biosciences, Caltag and Serotec) and FMO (fluorescence minus 
one). The results represent the percentage of positively stained cells in the total cell 
population exceeding the background staining signal.  
 
TranswellTM in vitro chemotaxis assay 
 
To analyze the functional migration activity of the peritoneal exudate cells towards 
recombinant KC in the presence or absence of an anti-KC antibody, a 96-well 
Neuroprobe ChemoTx Chemotaxis plate (Receptor Technologies, Adderbury, UK) 
with 5µm pore polycarbonate filters was used, as previously described [21]. 
Peritoneal exudates from wild-type FVB/N mice were obtained by peritoneal lavage 
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12 hours post 4% thioglycollate injection and re-suspended at a concentration of 8 x 
106 cells/ml in serum-free RPMI 1640 media. The chemotactic factor; murine 
recombinant mrKC (Peprotech, UK), diluted in serum-free RPMI-1640 to 10ng/ml 
and with or without 0.1 µg/ml or 10µg/ml monoclonal anti-mouse CXCL1/KC 
antibody (R&D Systems), was added to the lower chamber. Following placement of 
the filter membrane over the lower wells, 25µl cells (2 x 105) were added to the upper 
chamber of each well. The plate was incubated for 4 hours at 37°C with 5% CO2. 
Inserts were removed and the number of neutrophils that migrated into the bottom 
chamber was determined by counting using a haemocytometer and trypan blue. For 
each experiment, the % migration after subtraction of the control (RPMI medium 
alone) was given for KC alone (no anti-KC) and for two concentrations of anti-KC 
antibody. 
 
Bioluminescence Neutrophil Trafficking Model 
To establish an efficient model to track and quantify neutrophil migration, we 
developed a neutrophil trafficking model using a luc+ transgenic donor mouse line in 
conjunction with bioluminescent imaging (Fig. 1). Expression of the luciferase 
reporter gene is detectable in all tissues including white blood cells of the transgenic 
β-actin-luc+ mice. It has been demonstrated that luc+ cells emit visible light photons 
that penetrate tissues and are externally and quantitatively detectable with high 
sensitivity [22]. Thus, 4 x 106 luc+ donor neutrophils were adoptively transferred 
intravenously (i.v.) via tail-vein of wild-type FVB/N recipients with DSS-induced 
colitis. Naïve wild-type FVB/N mice with or without transferred luc+ donor 
neutrophils were included as appropriate control groups. Bioluminescence imaging 
was performed, as previously described [23], using an IVIS 100 charge-coupled 
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device (CCD) imaging system (Xenogen, Alameda, CA.) at 2, 4, 16-22 h post 
adoptive cell transfer. Briefly, the recipient mice were injected i.p. with the exogenous 
substrate D-Luciferin (120mg/kg bodyweight) (BioThema AB, Sweden), following 
gaseous anesthesia with isoflurane and transferred to the imaging chamber. Emission 
images were collected with 2 minute integration times. Following the whole-body 
bioluminescent imaging, the mice were injected with an additional dose of D-
luciferin. Five minutes later, the mice were sacrificed and the organs were removed 
and imaged for 2 minutes. Bioluminescent signal was quantified by creation of 
regions of interest (ROIs). To standardize the data, light emission was quantified from 
the same surface area (ROI) for each organ type. In addition, background light 
emission, taken from ROIs created on organs of non-recipient non-DSS control 
animals, was subtracted from test organs. Imaging data was analyzed and quantified 
with Living Image Software (Xenogen) and expressed as photons/second/cm2. 
 
Use of the model to show inhibition of neutrophil infiltration into inflamed tissue 
by anti-KC 
DSS recipient mice (3 and 5 respectively) received purified isotype control rat IgG2aκ 
(BD Pharmingen) or a monoclonal rat anti-mouse CXCL1/KC antibody (R&D 
Systems) at a concentration of 20µg / mouse i.p., 1 hour pre-adoptive transfer of the 
luc+ peritoneal neutrophils. Four hours, post adoptive cell transfer, whole-body and ex 
vivo bioluminescent organ imaging was carried out in the same manner as described 
above. 
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Statistics 
Data are expressed as means ± SEM unless otherwise stated. Statistical significance 
was determined with the unpaired Student’s t-test using commercially available 
statistic software (GraphPad Software, San Diego, CA.). P values <0.05 were 
considered as statistically significant (*p<0.05, **p<0.01, ***p<0.001). 
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Results 
Phenotypic characterization of the peritoneal exudate  
To determine neutrophil purity and the overall phenotype profile of the peritoneal 
exudate cells 12 h post thioglycollate-induction of peritonitis, immunofluorescence 
flow cytometry was performed. The data revealed a neutrophil purity of 80%, i.e. 
LY6G+ cells (Fig. 1a), with clear expression of the activation molecule CD69 on these 
neutrophils as shown by mean fluorescence intensity (Fig. 1b). CXCR2, the major 
receptor for human IL-8 and the murine homologs KC and MIP-2, was expressed on 
39% of the neutrophils (Fig. 1c). The remaining 20% of the exudate consisted of 10% 
T lymphocytes (CD3+) and the rest being macrophages (F4/80+), NK cells (DX5+), 
dendritic cells (CD11c+) and B cells (B220+) (data not shown). Thus, the high 
percentage of activated neutrophils in the peritoneal exudate population demonstrates 
that these are suitable for adoptive transfer and neutrophil trafficking studies. 
 
Recombinant KC-stimulated neutrophil chemotaxis in vitro is reduced in the 
presence of anti-KC  
The chemotactic capability of the peritoneal exudate cells towards mrKC and the 
ability of an anti-KC antibody to inhibit this chemotaxis was examined in vitro using 
a Transwell system. Addition of mrKC to the bottom chamber of a 96-well 
Neuroprobe Chemotx plate induced mobilization of peritoneal exudate neutrophils 
from the upper chamber. This migration was reduced by two different concentrations 
of anti-KC. In the presence of mrKC, there was an 8% increase in % neutrophil 
transmigration compared to the RPMI medium control and this value was decreased 
to 2.8% and 1.5% by 0.1µg/ml  and 10µg/ml anti-KC, respectively (Fig. 1d). This 
chemotaxis assay confirmed the suitability of the peritoneal exudate cells for adoptive 
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transfer. Neutrophil migration towards recombinant Macrophage Inflammatory 
Protein-2 (MIP-2) instead of mrKC was also tested with similar results (data not 
shown).  
 
Kinetic analysis of neutrophil trafficking in DSS-induced colitis 
In the absence of inflammation, neutrophils (activated and responsive to KC) did not 
migrate to the colons of naïve mice indicating the necessity for localized 
gastrointestinal inflammation (Figures 4 and 5). Acute DSS colitis was, therefore, 
induced in recipient mice. Inflammation was confirmed by assessing body weight 
change and total daily disease activity index (DDAI) (Fig. 2a-b) and by the significant 
increases in levels of KC and the pro-inflammatory cytokines IL-1β and IL-6 in the 
distal colons of the DSS mice as previously reported [15, 24] (Fig. 2c). In addition, we 
and others have provided both histological and MPO data confirming the colonic 
tissue damage caused by DSS administration [25-29]. Following induction of colitis, 
the temporal recruitment of neutrophils in living animals was analyzed by performing 
whole-body and ex vivo organ bioluminescence imaging at 2, 4, and 16-22 h 
following adoptive transfer of luc+ peritoneal exudate cells. Whole-body imaging 
confirmed presence of transferred viable neutrophils in recipient mice at all time 
points (data not shown). At the early time points of 2 and 4 h post adoptive cell 
transfer, ex vivo imaging of organs revealed high neutrophil infiltration, as measured 
by bioluminescent signal, in the lungs, spleens and livers of recipient DSS mice (Fig. 
3 c, d and e). The neutrophil signal in the colon was increased by 93% at 4 h 
compared to 2 h (Fig. 4a). At the later time point of 16-22 h, neutrophil presence in 
the colon remained high (Fig. 3a) but had decreased in the spleen, liver and lungs 
(Fig. 3c, d and e). Thus, the data show a robust signal in the inflamed colon at all time 
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points post cell transfer. There was no evidence of neutrophil recruitment to the small 
intestines of DSS recipient mice at any of the time points studied (data not shown).  
 
Effects of KC blockade on neutrophil influx during DSS-induced colitis 
To illustrate the potential of the bioluminescence neutrophil trafficking model, we 
assessed the effect of a chemokine blocking antibody, anti-KC. Four hours post 
adoptive transfer of luc+ neutrophils from transgenic donors, a clear bioluminescent 
signal was apparent in the whole-body images of all the recipient DSS mice and of the 
naïve control mice in contrast to the non-recipient non-DSS control, specifically in the 
upper part of the body and in the inguinal lymph nodes (Fig. 4a). These images 
confirm that the recipient mice received viable luciferase-expressing cells that can be 
detected in vivo. However, since some attenuation of optical signal is expected to 
occur with tissue depth, ex vivo imaging of the organs is necessary for accurate 
visualization and quantitation of neutrophil localization. 
 Ex vivo imaging of the organs revealed high neutrophil presence (i.e. 
bioluminescent signal) in the spleens and  lungs of the IgG control-treated and anti-
KC-treated DSS recipients, confirming our observations from the whole-body 
imaging. There was no significant increase or decrease in neutrophil recruitment to  
liver, spleen or lungs in the anti-KC treated group compared to the IgG control-treated 
group [Fig. 5b (i) and ( ii)]. However, a significant reduction in the signal from the 
colons of the DSS-recipients that were treated with anti-KC compared to the IgG 
control-treated recipients was observed (Fig. 4b and Fig. 5a). Similar to the kinetic 
study, no bioluminescence signal was evident in the small intestines of both IgG 
control-treated and anti-KC treated groups (data not shown). In the naïve recipients, 
i.e. the control group, there was significantly higher localization of neutrophils in the 
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liver, spleen and lungs compared to the DSS recipient mice [Fig. 5b (i) and ( ii)]. 
However, in contrast to the DSS recipients, there was no bioluminescence signal 
evident in the naïve colons (Fig. 5a). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 14
Discussion 
In both human and experimental IBD, PMN invasion of the intestinal lamina propria 
and crypts correlates with tissue damage and clinical symptoms, suggesting that 
targeting neutrophil recruitment is a viable therapeutic strategy for IBD. This study 
presents a robust model to analyze the biology of neutrophil trafficking that can also 
be used in pre-clinical studies to evaluate new therapeutic compounds specifically 
aimed at blocking neutrophil recruitment. The first step in developing the model was 
to characterize the purity and functional properties of the neutrophil population from 
thioglycollate -induced peritonitis. Phenotypic analysis of the peritoneal exudate 
isolated 12 hours post i.p. administration of thioglycollate, revealed 80% neutrophil 
purity. In addition, the cells were activated and functionally responsive to 
recombinant KC in vitro and their chemotaxis was inhibited by the presence of an 
anti-KC antibody. These results showed that the post-thioglycollate peritoneal exudate 
population of neutrophils was appropriate for the adoptive transfer model. 
 
Bioluminescence imaging of whole-body and ex vivo organs was used to track and 
quantify neutrophil trafficking following adoptive transfer of luc+ peritoneal exudate 
cells from transgenic donors. This is a non-invasive technology allowing real-time 
detection of tagged cells in vivo using CCD cameras due to the detection of visible 
light produced by luciferase-catalyzed reactions [30]. In contrast to other imaging 
modalities such as Positron Emission Tomography (PET), Single photon emission 
computed tomography (SPECT) and Magnetic resonance imaging (MRI); 
bioluminescence imaging is less complicated, less labor intensive and relatively low 
cost while still providing quantitative, spatial and temporal data. In addition, 
bioluminescence overcomes the problems commonly encountered with using 
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fluorescent labels such as CFSE and GFP, namely the exponentially decreasing light 
intensity with tissue depth and the limited sensitivity and specificity as a result of 
endogenous tissue autofluorescence [31, 32]. So far, bioluminescence has been used 
to monitor infection progression, transgene expression, tumor growth and metastasis, 
transplantation, toxicology and gene therapy [30]. In the context of cell tracking, 
Sheikh et al., successfully used bioluminescence imaging to track bone marrow 
mononuclear cell homing in ischemic myocardium [33], while Costa et al., used a 
retroviral vector containing luciferase and GFP to illuminate the migratory patterns of 
CD4+ T cells in a mouse model of multiple sclerosis [34]. These and other studies 
have shown robust correlation between cell numbers and bioluminescence signals 
[23]. The results of the present study demonstrated that the adoptively transferred 
neutrophils preferentially migrated to the diseased sites in the recipient animals with 
DSS-induced colitis, with high infiltration of the colon at all time points investigated. 
In contrast, high transit through the lungs and spleen was evident at early time points 
following cell transfer but declined at the later time point. This is probably due to re-
direction of the transferred neutrophils to the inflamed colon with return to basal 
conditions in these organs. Since the route of administration of the donor cells was 
intravenous (i.v.), neutrophil localization to the lungs, liver and spleen of the recipient 
mice reflects the natural route of circulation. In fact, it is possible that the higher 
neutrophil presence in the inflamed colon at the later time points of 4h and 16-22h 
compared to 2h post adoptive transfer of cells is due to the fact that a recovery time of 
at least 2 hours is necessary to allow transferred cells to equilibrate in the circulation 
following i.v. administration. There was significantly higher neutrophil presence in 
the lungs, liver and spleen of the naïve recipients compared to in the DSS recipients 
which was most likely due to the absence of gut inflammation. Similar findings have 
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been noted in previous studies where neutrophil presence in the spleen declined in 
patients with severe inflammatory disease compared to normal subjects. The 
explanation for this being that the pooled cells had been re-directed to inflammatory 
foci [35, 36]. In addition, we investigated the utility of the bioluminescence model as 
a tool to dissect the biology of and test new drugs that target neutrophil migration 
using a blocking antibody against KC. Significant inhibition of neutrophil recruitment 
to the inflamed colons of the anti-KC treated mice compared to IgG control-treated 
was clearly evident using this system. Interestingly, it has been reported that treatment 
of mice with TNBS-induced colitis with anti-KC ameliorated disease by reducing 
neutrophil migration and MPO [37].  
 
The bioluminescence model presented here has definite and distinct advantages over 
other ex vivo techniques used to track neutrophil recruitment. First and foremost, the 
necessity for pre-labeling of cells is removed as the donor cells used constitutively 
express luciferase. This eliminates the common problems associated with cell-labeling 
such as alteration of cellular functions, variable labeling efficiency and elution of 
label from the cells of interest. In addition, our technique allows direct ex vivo 
visualization without any need for further processing of the tissues, in contrast to 
immunohistochemistry and MPO analysis. Histology is labor intensive and tedious 
while MPO assays can be problematic and do not distinguish between neutrophils and 
macrophages.  
 
In conclusion, this study presents a robust model to track neutrophil recruitment 
which can be used to complement other available methods traditionally used for 
tracking neutrophils. In addition to experimental models of IBD, this versatile 
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technique will be useful for monitoring neutrophil trafficking during inflammatory 
responses in a range of disease settings and constitutes a novel approach for the 
assessment of potential therapeutics that aim to reduce neutrophil infiltration. Thus it 
can be used as an informative and specific tool for both the pharmaceutical industry 
and the basic research community. 
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 Figure Legend 
   
Figure 1. Phenotypic and functional characterization of the peritoneal exudate 
population. Cells were isolated from the peritoneum of FVB/N mice 12 h after i.p. 
injection with thioglycollate. For the phenotypic analysis, single cell suspensions 
were stained with flurochrome-labeled mAbs and analyzed by flow cytometry in 
which 20,000 events were recorded. (a) Percentage of neutrophils (i.e. Ly-6G+ cells, 
grey area) present in the peritoneal exudate compared to isotype control antibody 
(black area). (b) Activation status of the neutrophils using anti-CD69 mAb (grey area) 
or irrelevant control antibody (black area). (c) Percentage of the LY-6G+ neutrophils 
that were CXCR2+. Plots shown are representative of five separate experiments, and 
the mean values are indicated. (d) In vitro chemotaxis assay in which migrated cells 
from triplicate wells of the lower chambers were pooled and counted in trypan blue. 
For each experiment, the % migration after subtraction of the control (medium alone) 
was given for KC (alone, no anti-KC) and for two concentrations of anti-KC antibody 
(0.1µg/ml and 10µg/ml), 4 hr post incubation at 37°C. Plots shown are representative 
of three separate experiments using pools of 3-6 mice; *p ≤ 0.05, **p<0.01.  
 
Figure 2. Inflammation markers in DSS-induced colitis in FVB/N mice. (a) Mean % 
body weight changes in wild type FVB/N mice from day 0 of treatment with 4% 
(w/v) DSS in drinking water for 5 days followed by 1 day of water. (b) Stool 
consistency and fur texture/posture were used to generate a daily disease activity 
index (DDAI). DSS-treated groups n = 4 and non-DSS control n = 1. (c) Treatment 
with DSS significantly increased KC levels and levels of the pro-inflammatory 
cytokines IL-1β and IL-6; in the distal colons of the mice. n = 5-6 per group; 
**p<0.01, ***p<0.001. 
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 Figure 3. Kinetic analysis of neutrophil trafficking in vivo.  Bioluminescent signal in 
organs dissected from DSS recipient mice at 2, 4 and 16- 22 h post adoptive transfer 
with luc+ exudate cells. Neutrophil trafficking kinetics to (a) colon, (b) mesenteric 
lymph nodes (MLNs), (c) spleen, (d) liver and (e) lungs are shown. DSS-treated 
groups n = 5-8. 
 
Figure 4. Effect of anti-mouse KC on neutrophil trafficking. (a). Representative 
whole body bioluminescence images of wt FVB/N recipients with DSS-induced 
colitis treated with isotype control rat IgG2a or anti-KC antibody, 4 hours post 
adoptive transfer with luc+ cells. Non-DSS/naïve  recipients were also included as a 
control group. 
(b) Ex vivo images of colon of (i) non-DSS non-recipient negative control (ii) non-
DSS/naïve recipient mouse and DSS recipient mice treated with (iii) IgG control or 
(iv) anti-KC (20µg/mouse). Non-DSS/naïve recipient, non-DSS- treated and DSS-
treated groups n = 3-5.  
 
 
Figure 5. Anti-KC administration markedly reduces neutrophil trafficking to the 
colons of mice with DSS-induced colitis. Summary of bioluminescent signal in (a) 
colons and mesenteric lymph nodes (MLNs) and b (i) liver and spleen and b (ii) lungs 
dissected from naïve controls and DSS mice treated with IgG control or anti-KC 
antibody, 4 hours post adoptive transfer with luc+ cells. NB: Mean signal from the 
colons of naïve recipients was below the background light emission from the non-
recipient control colons. p ≤ 0.05; n = 3-5 per group. 
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